Cancer Prevention Research CR Magazine AM No Deadline
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Cancer Prevention Research 1, 21, June 1, 2008. Published Online First April 14, 2008;
doi: 10.1158/1940-6207.CAPR-07-0011
© 2008 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Perspective on This Article
Right arrow All Versions of this Article:
1940-6207.CAPR-07-0011v1
1/1/21    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cho, N. L.
Right arrow Articles by Bertagnolli, M. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cho, N. L.
Right arrow Articles by Bertagnolli, M. M.
Related Collections
Right arrowCommentary

Research Articles

Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial

Nancy L. Cho1, Mark Redston2, Ann G. Zauber5, Adelaide M. Carothers1, Jason Hornick2, Andrew Wilton7, Stephen Sontag8, Norman Nishioka4, Francis M. Giardiello9, John R. Saltzman3, Chris Gostout10, Craig J. Eagle6, Ernest T. Hawk11 and Monica M. Bertagnolli1

Authors' Affiliations: Departments of 1 Surgery, 2 Pathology, and 3 Medicine, Brigham and Women's Hospital; 4 Department of Medicine, Massachusetts General Hospital, Boston Massachusetts; 5 Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center; 6 Pfizer, Inc., New York, New York; 7 Institute for Clinical Evaluative Sciences, Toronto, Ontario, Canada; 8 Hines Veteran's Administration Medical Center, Hines, Illinois; 9 Department of Medicine, The Johns Hopkins School of Medicine, Baltimore, Maryland; 10 Department of Medicine, The Mayo Clinic, Rochester, Minnesota; and 11 National Cancer Institute, Bethesda, Maryland

Requests for reprints: Monica M. Bertagnolli, Department of Surgery, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115. Phone: 617-732-8910; Fax: 617-582-6177; E-mail: mbertagnolli{at}partners.org.

Aberrant crypt foci (ACF) are the earliest visible neoplastic lesions in the colorectum. The natural history of these lesions and their role in the adenoma-carcinoma sequence are unknown. We studied ACF in a subset of patients randomized to placebo (n = 17), celecoxib (200 mg twice daily; n = 15), or celecoxib (400 mg twice daily; n = 13) in the Adenoma Prevention with Celecoxib (APC) trial. Magnification chromoendoscopy was done to identify, count, and biopsy ACF within the rectum at baseline and after 8 to 12 months of treatment. A total of 655 ACF were identified in 45 patients. We examined 70 of these ACF histologically, and all 70 were nondysplastic. Cohort characteristics and APC trial treatment results for substudy patients were similar to those of the overall APC trial. There was no significant modulation of ACF by celecoxib (versus placebo; P = 0.77). Immunohistochemical comparison of ACF with adjacent normal mucosa showed that ACF had an increased proliferative index as determined by Ki-67 (P < 0.0001), but lacked other features of neoplasia such as increased cyclooxygenase-2 expression and microvessel density, nuclear localization of β-catenin, or decreased expression of the tumor suppressors SMAD4, Estrogen Receptor {alpha}, or MGMT. Only baseline SMAD4 expression in ACF correlated with posttreatment adenoma recurrence (independent of treatment arm; P = 0.01). The presence or number of nondysplastic ACF did not correlate with a higher risk of synchronous advanced or recurrent adenomas. Our overall results indicated that nondysplastic ACF were not accurate surrogate endpoint biomarkers of recurrent colorectal adenomas in the APC trial.


Commentary

Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention
Peter Lance and Stanley R. Hamilton
Cancer Prevention Research 2008 1: 4-8. [Full Text] [PDF]



This article has been cited by other articles:


Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
P. Sena, L. Roncucci, L. Marzona, F. Mariani, S. Maffei, A. Manenti, and A. De Pol
Altered Expression of Apoptosis Biomarkers in Human Colorectal Microadenomas
Cancer Epidemiol. Biomarkers Prev., February 1, 2010; 19(2): 351 - 357.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
A. P. Femia, A. Giannini, M. Fazi, E. Tarquini, M. Salvadori, L. Roncucci, F. Tonelli, P. Dolara, and G. Caderni
Identification of Mucin Depleted Foci in the Human Colon
Cancer Prevention Research, December 1, 2008; 1(7): 562 - 567.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
E. Szabo
Assessing Efficacy in Early-Phase Cancer Prevention Trials: The Case of Oral Premalignancy
Cancer Prevention Research, October 1, 2008; 1(5): 312 - 315.
[Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
R. G. Stevens, T. P. Pretlow, D. P. Hurlstone, C. Giardina, and D. W. Rosenberg
Comment re: "Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention" and "Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial"
Cancer Prevention Research, August 1, 2008; 1(3): 215 - 216.
[Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
P. Lance and S. R. Hamilton
Comment re: "Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention" and "Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial"
Cancer Prevention Research, August 1, 2008; 1(3): 216 - 216.
[Full Text] [PDF]

Home page
 Cancer Prevention ResearchHome page
A. G. Zauber, M. M. Bertagnolli, and for the APC Trial Investigators
Comment re: "Sporadic Aberrant Crypt Foci Are Not a Surrogate Endpoint for Colorectal Adenoma Prevention" and "Aberrant Crypt Foci in the Adenoma Prevention with Celecoxib Trial"
Cancer Prevention Research, August 1, 2008; 1(3): 216 - 216.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2008 by the American Association for Cancer Research.